[go: up one dir, main page]

NO20081854L - Antagonistantistoff rettet mot calcitonin genrelatert peptid, og anvendelser av samme - Google Patents

Antagonistantistoff rettet mot calcitonin genrelatert peptid, og anvendelser av samme

Info

Publication number
NO20081854L
NO20081854L NO20081854A NO20081854A NO20081854L NO 20081854 L NO20081854 L NO 20081854L NO 20081854 A NO20081854 A NO 20081854A NO 20081854 A NO20081854 A NO 20081854A NO 20081854 L NO20081854 L NO 20081854L
Authority
NO
Norway
Prior art keywords
antagonist antibody
directed against
same
antibody directed
related peptide
Prior art date
Application number
NO20081854A
Other languages
English (en)
Other versions
NO344099B1 (no
Inventor
Arnon Rosenthal
Joerg Zeller
Kristian Todd Poulsen
Yasmina Noubia Abdiche
Jaume Pons
Sierra Jones Collier
Original Assignee
Teva Pharmaceuticals Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081854(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceuticals Int Gmbh filed Critical Teva Pharmaceuticals Int Gmbh
Publication of NO20081854L publication Critical patent/NO20081854L/no
Publication of NO344099B1 publication Critical patent/NO344099B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sammendrag Det beskrives fremgangsmåter for å hindre eller behandle CGRP-assosierte forstyrrelser så som vasomotorsymptomer, inkluderende hodepiner (for eksempel migrene, kluster hodepine og spenningshodepine) og varmetokter, ved å administrere en anti-CGRP antagonist antistoff. Antagonist antistoff Gl og antistoff avledet fra Gl rettet mot CGRP er også beskrevet.
NO20081854A 2005-11-14 2008-04-16 Antagonistantistoff rettet mot calcitonin genrelatert peptid, og anvendelser av samme NO344099B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73662305P 2005-11-14 2005-11-14
PCT/IB2006/003181 WO2007054809A2 (en) 2005-11-14 2006-11-02 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Publications (2)

Publication Number Publication Date
NO20081854L true NO20081854L (no) 2008-05-19
NO344099B1 NO344099B1 (no) 2019-09-02

Family

ID=37909474

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20081854A NO344099B1 (no) 2005-11-14 2008-04-16 Antagonistantistoff rettet mot calcitonin genrelatert peptid, og anvendelser av samme
NO20190202A NO344605B1 (no) 2005-11-14 2019-02-13 Anvendelse av anti-CGRP antagonist antistoff
NO2019043C NO2019043I1 (no) 2005-11-14 2019-12-09 Fremanezumab

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20190202A NO344605B1 (no) 2005-11-14 2019-02-13 Anvendelse av anti-CGRP antagonist antistoff
NO2019043C NO2019043I1 (no) 2005-11-14 2019-12-09 Fremanezumab

Country Status (37)

Country Link
US (20) US8007794B2 (no)
EP (6) EP3178493A1 (no)
JP (1) JP5123197B2 (no)
KR (2) KR20080068062A (no)
CN (2) CN103421114B (no)
AP (1) AP2008004467A0 (no)
AU (1) AU2006313434B2 (no)
BR (1) BRPI0618705B8 (no)
CA (1) CA2626120C (no)
CR (1) CR9975A (no)
CU (1) CU23872B1 (no)
CY (3) CY1120249T1 (no)
DK (3) DK3045182T3 (no)
EA (1) EA015526B1 (no)
EC (1) ECSP088451A (no)
ES (3) ES2664854T3 (no)
GE (1) GEP20115333B (no)
HR (2) HRP20180752T1 (no)
HU (3) HUE036944T2 (no)
IL (3) IL190876A (no)
LT (3) LT2380592T (no)
LU (2) LUC00119I2 (no)
MA (1) MA30136B1 (no)
ME (1) ME00419B (no)
MY (1) MY153249A (no)
NL (1) NL300997I2 (no)
NO (3) NO344099B1 (no)
NZ (1) NZ568237A (no)
PL (3) PL1957106T5 (no)
PT (3) PT1957106E (no)
RS (3) RS20080200A (no)
SI (3) SI2380592T1 (no)
SV (1) SV2008002905A (no)
TN (1) TNSN08213A1 (no)
UA (1) UA94244C2 (no)
WO (1) WO2007054809A2 (no)
ZA (1) ZA200803484B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
EP3115062A1 (en) 2008-03-04 2017-01-11 Labrys Biologics Inc. Methods of treating inflammatory pain
WO2009109911A1 (en) * 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
JP5524177B2 (ja) 2008-04-09 2014-06-18 フェリン ファーマシューティカルズ インコーポレイテッド ほてりのためのステロイド治療
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
CN102405369B (zh) 2009-03-16 2016-04-20 考尔得产品公司 无菌联接装置
IN2012DN02521A (no) * 2009-08-28 2015-08-28 Rinat Neuroscience Corp
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
KR102205752B1 (ko) 2011-02-10 2021-01-22 벨로스 미디어 인터내셔널 리미티드 화상 처리 장치 및 화상 처리 방법
AU2012258980B8 (en) * 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
BR112013029951B1 (pt) 2011-05-20 2020-10-20 Alderbio Holdings Llc composição farmacêutica e uso de anticorpos ou fragmentos de anticorpos anti-cgrp para tratar ou prevenir formas de diarreia crônicas e agudas
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
AU2013211929B2 (en) * 2012-01-26 2016-05-26 Christopher J. Soares Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
SG10201906172XA (en) * 2013-07-03 2019-08-27 Alder Biopharmaceuticals Inc Regulation of glucose metabolism using anti-cgrp antibodies
US9770581B2 (en) 2013-07-23 2017-09-26 Colder Products Company Aseptic coupling devices
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
WO2015176017A1 (en) * 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders
EP3180069B1 (en) 2014-08-17 2020-05-13 Nine Continents Medical, Inc. Miniature implatable neurostimulator system for sciatic nerves and their branches
US12053630B2 (en) 2014-08-17 2024-08-06 Coloplast A/S Implantable pulse generator with automatic jump-start
AU2015318008B2 (en) * 2014-09-15 2021-05-20 Amgen Inc. Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
EA201890578A1 (ru) * 2015-09-24 2018-12-28 Тева Фармасьютикалз Интернэшнл Гмбх Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли
CA3007018A1 (en) * 2016-01-28 2017-08-03 Eli Lilly And Company Cgrp antibodies and uses thereof
EP3411066A1 (en) 2016-02-01 2018-12-12 Eli Lilly and Company Parathyroid hormone anti-rankl antibody fusion compounds
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF
US10688412B2 (en) * 2016-07-25 2020-06-23 Cehpalon, Inc. Affinity chromatography wash buffer
CA3035561A1 (en) 2016-09-02 2018-03-08 Christopher J. Soares Use of cgrp receptor antagonists in neuroprotection and neurological disorders
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP2019529463A (ja) * 2016-09-23 2019-10-17 テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー 群発頭痛の治療方法
CN106442967B (zh) * 2016-09-27 2018-05-15 鸿运华宁（杭州）生物医药有限公司 一种检测跨膜蛋白单克隆抗体亲和力的方法
GB2557655A (en) 2016-12-14 2018-06-27 Teva Pharma Medical injection device packaging
CN110621343A (zh) 2017-03-02 2019-12-27 贝丝以色列女执事医疗中心 选择对针对降钙素基因相关肽的抗体有反应的头痛患者
WO2018236873A1 (en) * 2017-06-19 2018-12-27 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
KR102618831B1 (ko) 2017-06-21 2023-12-28 세파론 엘엘씨 양이온 교환 크로마토그래피 세척 완충액
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
CN112040949A (zh) * 2018-02-23 2020-12-04 瑞美德生物医药科技有限公司 降钙素基因相关肽(cgrp)拮抗剂抗体
US11295402B2 (en) 2018-03-28 2022-04-05 Bank Of America Corporation Blockchain-based property repair
US10498808B2 (en) 2018-03-28 2019-12-03 Bank Of America Corporation Blockchain-based property management
US11475422B2 (en) 2018-03-28 2022-10-18 Bank Of America Corporation Blockchain-based property management
MA52202A (fr) 2018-04-02 2021-02-17 Amgen Inc Compositions d'érénumab et utilisations de celles-ci
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
JP7465260B2 (ja) 2018-09-20 2024-04-10 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー 充填済シリンジおよび自動注射器
EP3906316A4 (en) * 2018-12-31 2022-11-30 United Neuroscience Limited PEPTIDE IMMUNOGENS FOR TARGETING CALCITONINGEN-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR THE PREVENTION AND TREATMENT OF MIGRAINE
MA54704A (fr) 2019-01-08 2022-04-13 H Lundbeck As Traitement aigu et traitement rapide de maux de tête à l'aide d'anticorps anti-cgrp
CN114585411A (zh) 2019-08-27 2022-06-03 考尔得产品公司 一次性无性无菌流体联接器
JP2022547948A (ja) * 2019-09-09 2022-11-16 ザ・ユニバーシティ・オブ・シカゴ 片頭痛の処置のための併用療法
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
CN112274302B (zh) * 2020-11-24 2021-07-13 四川大学华西医院 一种多单元可调的智能化椎间融合器
IT202000029459A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Terapia dei disturbi emotivi
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
US20250109188A1 (en) 2021-08-24 2025-04-03 Cgrp Diagnostics Gmbh Preventative treatment of migraine
CA3243118A1 (en) * 2022-01-21 2023-07-27 Pralonir S.A.S. ACTIVE IMMUNIZATION TO REDUCE ARTHRITIS, NEUROPATHIC AND CANCER PAIN
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
WO2024229245A2 (en) * 2023-05-04 2024-11-07 Alexion Pharmaceuticals, Inc. High throughput fab antibody fragment generation and ranking

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4814567A (en) 1987-07-08 1989-03-21 Darko Jorge Lazaneo Dragicevic Electro-thermic resonance system for heating liquid
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69034078T2 (de) 1989-03-21 2004-04-01 Vical, Inc., San Diego Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
ES2080802T3 (es) 1989-07-10 1996-02-16 Amylin Pharmaceuticals Inc Uso de un antagonista de amilina en la preparacion de un medicamento para el tratamiento de la obesidad e hipertension intrinseca y desordenes asociados.
EP1645635A3 (en) 1989-08-18 2010-07-07 Oxford Biomedica (UK) Limited Replication defective recombinant retroviruses expressing a palliative
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
DE4139664A1 (de) 1991-12-02 1993-06-03 Diagen Inst Molekularbio Vorrichtung und verfahren zur isolierung und reinigung von nukleinsaeuren
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0650370A4 (en) 1992-06-08 1995-11-22 Univ California METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
WO1993025698A1 (en) 1992-06-10 1993-12-23 The United States Government As Represented By The Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
DE4242396C2 (de) 1992-12-09 1995-01-05 Helopharm Petrik Co Kg Aralkyldiaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
ES2188612T3 (es) 1993-04-22 2003-07-01 Skyepharma Inc Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso.
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
CA2158937C (en) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Recombinant alphavirus vectors
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
CN1099868C (zh) 1993-11-16 2003-01-29 斯卡法玛公司 具有控制释放活性成分作用的囊
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
EP0772689B1 (en) 1994-05-09 2007-12-19 Oxford Biomedica (UK) Limited Retroviral vectors having a reduced recombination rate
DE69433747D1 (de) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
JPH11512396A (ja) * 1995-09-05 1999-10-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
WO1997041223A1 (en) 1996-04-15 1997-11-06 The University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
WO1997042338A1 (en) 1996-05-06 1997-11-13 Chiron Corporation Crossless retroviral vectors
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
WO1998003534A1 (en) 1996-07-23 1998-01-29 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP3734315B2 (ja) 1996-08-26 2006-01-11 株式会社小松製作所 曲げ加工方法および曲げ加工装置
WO1998009630A1 (en) * 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
NZ334543A (en) 1996-09-10 2000-06-23 Thomae Gmbh Dr K Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
JP2002525371A (ja) 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Ｃｇｒｐリガンドとしてのベンゾイミダゾリニルピペリジン
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) * 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
EP1158997A2 (en) 1999-03-09 2001-12-05 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) † 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
WO2003027252A2 (en) 2001-09-27 2003-04-03 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
WO2003093472A2 (de) 2002-05-06 2003-11-13 Grünenthal GmbH Cgrp bindende nukleinsäuren
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
ES2616539T3 (es) * 2002-06-05 2017-06-13 Bristol-Myers Squibb Company Antagonistas de receptores de péptidos relacionados con el gen de calcitonina
AU2003244817B2 (en) * 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
KR101070213B1 (ko) 2002-08-12 2011-10-06 액타비스 그룹 에이취에프. 건선 치료를 위한 ｃｇｒｐ 안타고니스트 화합물의 용도
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
MXPA05005921A (es) 2002-12-02 2005-10-19 Abgenix Inc Anticuerpos dirigidos a factor de necrosis tumoral y sus usos.
US7449616B2 (en) 2002-12-24 2008-11-11 Pfizer Inc. Anti-NGF antibodies and methods using same
JP4584914B2 (ja) * 2003-03-14 2010-11-24 メルク・シャープ・エンド・ドーム・コーポレイション ベノジアゼピンスピロヒダントインｃｇｒｐ受容体拮抗物質
US7189722B2 (en) 2003-03-14 2007-03-13 Merck & Co., Inc. Aryl spirohydantoin CGRP receptor antagonists
EP1606264B1 (en) * 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
JP4690313B2 (ja) * 2003-03-14 2011-06-01 メルク・シャープ・エンド・ドーム・コーポレイション カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
ATE394400T1 (de) * 2003-03-14 2008-05-15 Merck & Co Inc Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
ATE466860T1 (de) 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
CA2532064A1 (en) 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine cgrp receptor antagonists
DE102004008261B3 (de) 2004-02-20 2005-09-29 Mtu Friedrichshafen Gmbh Verfahren zur Steuerung und Regelung einer Brennkraftmaschinen-Generator-Einheit
EP1722792A1 (de) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
JP2007533685A (ja) 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 偏頭痛を治療するためのセロトニン再吸収阻害剤と組合わせたｃｇｒｐアンタゴニストの使用
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
WO2007025212A2 (en) 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the treatment of visceral pain or pain caused by cancer treatment
WO2007025286A2 (en) 2005-08-26 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Therapy procedure for drug delivery for trigeminal pain
WO2007035906A2 (en) 2005-09-21 2007-03-29 The Regents Of The University Of California Systems and methods for imaging-treatment of pain
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
US8071770B2 (en) 2005-11-18 2011-12-06 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
EP2049532B1 (en) 2006-07-21 2010-06-02 Vertex Pharmaceuticals, Inc. Cgrp receptor antagonists
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
EP3115062A1 (en) 2008-03-04 2017-01-11 Labrys Biologics Inc. Methods of treating inflammatory pain
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
IN2012DN02521A (no) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
JO3330B1 (ar) 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
AU2012258980B8 (en) 2011-05-20 2017-06-15 H. Lundbeck A/S Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TR201904088T4 (tr) 2011-05-20 2019-05-21 Alderbio Holdings Llc Anti-CGRP bileşimleri ve bunların kullanımları.
US10249132B2 (en) 2012-10-29 2019-04-02 Netent Product Services Ltd. Architecture for multi-player, multi-game, multi-table, multi-operator and multi-jurisdiction live casino gaming
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
US9896502B2 (en) 2014-03-21 2018-02-20 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Also Published As

Publication number Publication date
US9115194B2 (en) 2015-08-25
ES2433251T5 (es) 2020-03-13
PL2380592T3 (pl) 2018-07-31
US9346881B2 (en) 2016-05-24
US9890210B2 (en) 2018-02-13
US20140147438A1 (en) 2014-05-29
US20170240625A1 (en) 2017-08-24
US8734802B1 (en) 2014-05-27
LUC00119I2 (no) 2020-07-10
NL300997I2 (nl) 2019-11-28
EP3178493A1 (en) 2017-06-14
BRPI0618705B8 (pt) 2021-05-25
LUC00126I2 (no) 2019-12-27
ECSP088451A (es) 2008-07-30
CY1120267T1 (el) 2019-07-10
ES2664854T3 (es) 2018-04-23
CN101309704A (zh) 2008-11-19
US20170081395A1 (en) 2017-03-23
CU20080088A7 (es) 2012-06-21
IL190876A0 (en) 2008-11-03
PT2380592T (pt) 2018-06-06
NL300997I1 (nl) 2019-07-03
NO344099B1 (no) 2019-09-02
IL248025A0 (en) 2016-11-30
EP3045182A1 (en) 2016-07-20
AP2008004467A0 (en) 2008-06-30
PT3045182T (pt) 2018-06-05
EA015526B1 (ru) 2011-08-30
EP1957106A2 (en) 2008-08-20
LT3045182T (lt) 2018-05-10
UA94244C2 (ru) 2011-04-26
US20150050267A1 (en) 2015-02-19
SI2380592T1 (en) 2018-06-29
EP2380592B1 (en) 2018-03-07
HRP20180753T1 (hr) 2018-08-24
US9328168B2 (en) 2016-05-03
EP3045182B1 (en) 2018-03-07
US20150361173A1 (en) 2015-12-17
PT1957106E (pt) 2013-12-26
RS57192B1 (sr) 2018-07-31
EP1957106B1 (en) 2013-10-16
HK1225627B (en) 2017-09-15
PL3045182T3 (pl) 2018-07-31
US20150291690A1 (en) 2015-10-15
CR9975A (es) 2008-06-02
US20190092841A1 (en) 2019-03-28
WO2007054809A3 (en) 2007-08-09
US20090220489A1 (en) 2009-09-03
US8586045B2 (en) 2013-11-19
KR20080068062A (ko) 2008-07-22
EP1957106B2 (en) 2019-07-24
US9884907B2 (en) 2018-02-06
RS57194B1 (sr) 2018-07-31
US9266951B2 (en) 2016-02-23
ZA200803484B (en) 2009-03-25
US8007794B2 (en) 2011-08-30
ES2433251T3 (es) 2013-12-10
US20160168244A1 (en) 2016-06-16
CY2019019I1 (el) 2019-11-27
KR20110114705A (ko) 2011-10-19
EP2380592A3 (en) 2012-06-06
US20150361171A1 (en) 2015-12-17
SV2008002905A (es) 2011-07-05
LTC2380592I2 (lt) 2020-05-11
US10329343B2 (en) 2019-06-25
US20120009192A1 (en) 2012-01-12
BRPI0618705B1 (pt) 2018-02-06
PL1957106T5 (pl) 2019-11-29
MY153249A (en) 2015-01-29
US9365648B1 (en) 2016-06-14
IL190876A (en) 2012-06-28
HRP20180752T1 (hr) 2018-06-15
NO2019043I1 (no) 2019-12-09
US20200247878A1 (en) 2020-08-06
HUE036940T2 (hu) 2018-08-28
LUC00119I1 (no) 2019-05-15
HK1125837A1 (en) 2009-08-21
TNSN08213A1 (fr) 2009-10-30
GEP20115333B (en) 2011-11-25
IL219503A0 (en) 2012-06-28
US20170240622A1 (en) 2017-08-24
NO20190202A1 (no) 2008-05-19
DK2380592T3 (en) 2018-03-19
DK1957106T4 (da) 2019-10-28
MA30136B1 (fr) 2009-01-02
HUE036944T2 (hu) 2018-08-28
EP3842458A1 (en) 2021-06-30
US20170240624A1 (en) 2017-08-24
WO2007054809A2 (en) 2007-05-18
LT2380592T (lt) 2018-05-10
CA2626120C (en) 2012-12-04
US9340614B2 (en) 2016-05-17
US20150361172A1 (en) 2015-12-17
LUC00126I1 (no) 2019-07-09
NZ568237A (en) 2011-11-25
EA200801094A1 (ru) 2008-10-30
ES2664421T3 (es) 2018-04-19
US9890211B2 (en) 2018-02-13
HUS1900035I1 (hu) 2019-07-29
US20240158481A1 (en) 2024-05-16
AU2006313434B2 (en) 2011-10-27
PL1957106T3 (pl) 2014-03-31
US20180162931A1 (en) 2018-06-14
ME00419B (me) 2011-10-10
SI1957106T2 (sl) 2019-09-30
US9884908B2 (en) 2018-02-06
SI1957106T1 (sl) 2014-02-28
CN103421114B (zh) 2017-09-22
US20220056114A1 (en) 2022-02-24
EP3069731A1 (en) 2016-09-21
NO344605B1 (no) 2020-02-10
CU23872B1 (es) 2013-03-27
US20130216535A1 (en) 2013-08-22
CY1120249T1 (el) 2019-07-10
CY2019019I2 (el) 2019-11-27
BRPI0618705A2 (pt) 2011-09-06
US20170240623A1 (en) 2017-08-24
DK3045182T3 (en) 2018-03-19
SI3045182T1 (en) 2018-08-31
CN101309704B (zh) 2012-10-10
LTPA2019015I1 (lt) 2019-08-26
RS20080200A (sr) 2009-07-15
EP2380592A2 (en) 2011-10-26
DK1957106T3 (da) 2013-11-04
KR101250049B1 (ko) 2013-04-04
CA2626120A1 (en) 2007-05-18
JP5123197B2 (ja) 2013-01-16
JP2009515942A (ja) 2009-04-16
AU2006313434A1 (en) 2007-05-18
CN103421114A (zh) 2013-12-04
US8597649B2 (en) 2013-12-03

Similar Documents

Publication Publication Date Title
NO20081854L (no) Antagonistantistoff rettet mot calcitonin genrelatert peptid, og anvendelser av samme
MX378344B (es) Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
NO20091926L (no) Anti-Notch3-agonist-antistoffer og deres anvendelse ved behandlingen av Notch3-relaterte sykdommer
EA200700136A1 (ru) Анти-cd154-антитела
NO20074238L (no) Fiksert dosering av HER-antistoffer
UA103602C2 (ru) АНТИТЕЛО, СПЕЦИФИЧНОЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКОГО ИЛИ ЛЕКАРСТВЕННОГО СРЕДСТВА
NO20084650L (no) Modifiserte humaniserte anti-interleukin-18 antistoffer
WO2007025249A3 (en) Methods for treatment of headaches by administration of oxytocin
NO20080246L (no) Anti-IGF1R-antistofformuleringer
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
UY28028A1 (es) Anticuerpos que enlazan a células asociadas ca 125/0772p y metodos de uso derivados
NO20082082L (no) Modulatorer for ATP-bindingskassettstransportere
WO2006104945A3 (en) Hepatitis c therapies
NO20070876L (no) Apolipoprotein A1 mimetics og anvendelser derav.
PE20091713A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
NO20053972L (no) Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav.
EA201170795A1 (ru) Антагонисты ccr2 группы 4-азетидинил-1-гетероарил-циклогексанола
WO2006116381A3 (en) Plasma or serum fraction for treatment or prevention of abnormal cell proliferation
NO20090304L (no) Fremgangsmater for a attenuere frigjoringen av inflammatoriske mediatorer og nyttige peptider
NO20082505L (no) Substtuert 5-heteroaryl-1-fenyl-pyrazol-cannabinoid-modulatorer
WO2009048658A3 (en) Optimized dengue virus entry inhibitory peptide (dn81)
DK2121746T3 (da) Potente og selektive mediatorer af kolesterolefflux
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: TEVA PHARMACEUTICALS INTERNATIONAL GMBH, CH

SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: FREMANEZUMAB; REG. NO/DATE: EU/1/19/1358 20190408

Spc suppl protection certif: 2019043

Filing date: 20191209

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: FREMANEZUMAB; REG. NO/DATE: EU/1/19/1358 20190408

Spc suppl protection certif: 2019043

Filing date: 20191209

Extension date: 20311102